Isatuximab

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 394 publications

Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma.

Plain language summary of a study on 30-minute intravenous infusion of isatuximab in people with newly diagnosed multiple myeloma.

Journal: Future oncology (London, England)
Published: April 27, 2026

Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.

Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma.

Journal: Expert opinion on investigational drugs
Published: April 23, 2026

Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.

Review of the first on-body injector (obi) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.

Journal: Expert opinion on drug delivery
Published: April 13, 2026

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).

Journal: Expert opinion on biological therapy
Published: March 17, 2026

Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Journal: Clinical lymphoma, myeloma & leukemia
Published: March 16, 2026

Rapid complete remission after one cycle of isatuximab-based quadruplet regimen in 1q21-positive primary plasma cell leukemia: a case report.

Rapid complete remission after one cycle of isatuximab-based quadruplet regimen in 1q21-positive primary plasma cell leukemia: a case report.

Journal: Frontiers in immunology
Published: February 22, 2026

Rapid regression of a bulky cranial lesion in high-risk multiple myeloma with isatuximab-based quadruplet induction.

Rapid regression of a bulky cranial lesion in high-risk multiple myeloma with isatuximab-based quadruplet induction.

Journal: International journal of hematology
Published: February 11, 2026

Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors.

Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors.

Journal: Science advances
Published: February 04, 2026

Descriptive Study of Current Routine Clinical Practice in the Management of Patients With Multiple Myeloma in Spain: CROMMAS Study.

Descriptive Study of Current Routine Clinical Practice in the Management of Patients With Multiple Myeloma in Spain: CROMMAS Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 16, 2026

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 06, 2026

Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.

Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.

Journal: Frontiers in immunology
Published: December 16, 2025

Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity.

Isatuximab induces antitumor activity in blastic plasmacytoid dendritic cell neoplasm through cellular cytotoxicity.

Journal: Leukemia
Published: December 15, 2025
Showing 1-12 of 394

Last Updated: 06/30/2026